Allan Gibofsky, MD, JD

home / authors / allan-gibofsky-md-jd

Articles

November 1st 2022

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

Vibeke Strand, MD Colby Evans, MD Allan Gibofsky, MD, JD

November 1st 2022

Biosimilar medicines: what are they and how are they used?

Vibeke Strand, MD Colby Evans, MD Allan Gibofsky, MD, JD

Plain Language Summary

November 1st 2022

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

Allan Gibofsky, MD, JD Colby Evans, MD Vibeke Strand, MD

November 1st 2022

What do patients and health care providers still need to know about biosimilar medicines?

Allan Gibofsky, MD, JD Colby Evans, MD Vibeke Strand, MD

Plain Language Summary

November 1st 2022

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

Allan Gibofsky, MD, JD Colby Evans, MD Vibeke Strand, MD

November 1st 2022

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective

Colby Evans, MD Allan Gibofsky, MD, JD Vibeke Strand, MD

November 1st 2022

What are the current challenges to wider biosimilar use in the United States?

Colby Evans, MD Allan Gibofsky, MD, JD Vibeke Strand, MD

Plain Language Summary

May 31st 2014

Current Therapeutic Agents and Treatment Paradigms for the Management of Rheumatoid Arthritis

Allan Gibofsky, MD, JD

May 31st 2014

Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis: A Synopsis

Allan Gibofsky, MD, JD

December 24th 2012

Overview of Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis

Allan Gibofsky, MD, JD

December 24th 2012

Comparative Effectiveness of Current Treatments for Rheumatoid Arthritis

Allan Gibofsky, MD, JD

Latest Updated Articles

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Jason Porter, MD, an expert on lung cancer

Published: July 24th 2024 | Updated: July 27th 2024

Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

Jason Porter, MD, an expert on lung cancer

Published: July 24th 2024 | Updated: July 27th 2024

Insights from the TROPION-Lung05 Trial at ASCO 2024

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School

Published: July 24th 2024 | Updated: July 27th 2024

Examining Trends, Future Directions in AI and Health Care

Aspirin tablets dissolving in water | Imaged credit: Victor Moussa - stock.adobe.com

Published: July 15th 2024 | Updated: July 27th 2024

No Sex Differences Identified in Aspirin Dosing for Secondary Prevention of ASCVD

Alfred L. Garfall, MD, an expert on multiple myeloma

Published: July 24th 2024 | Updated: July 27th 2024

Future Directions in the Management of Multiple Myeloma

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions